TABLE 9.
Percent of Pathogens Reported From Surgical Site Infections (SSIs) That Tested Resistant to Selected Antimicrobial Agents, by Period, 2011–2014
| Pathogen, antimicrobial | 2011 | 2012 | 2013 | 2014 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of isolates reported | % of isolates testeda | % Resistance | No. of isolates reported | % of isolates testeda | % Resistance | No. of isolates reported | % of isolates testeda | % Resistance | No. of isolates reported | % of isolates testeda | % Resistance | |
| Staphylococcus aureus | 5,152 | 8,435 | 8,577 | 8,738 | ||||||||
| OX/METH/CEFOX | 96.2 | 42.7 | 94.8 | 44.7 | 94.8 | 44.2 | 94.3 | 42.6 | ||||
| Enterococcus spp. | ||||||||||||
| E. faecium | 414 | 1,123 | 1,261 | 1,342 | ||||||||
| VAN | 97.3 | 64.0 | 96.3 | 59.7 | 96.2 | 60.6 | 95.9 | 58.4 | ||||
| E. faecalis | 1,192 | 2,936 | 3,474 | 3,554 | ||||||||
| VAN | 94.0 | 5.3 | 93.8 | 3.9 | 93.8 | 3.7 | 93.6 | 3.5 | ||||
| Klebsiella (pneumoniae/oxytoca) | 831 | 1,874 | 2,043 | 2,319 | ||||||||
| ESC4 | 81.7 | 10.6 | 78.8 | 9.7 | 80.4 | 9.6 | 81.1 | 11.3 | ||||
| Carbapenems | 59.6 | 4.6 | 66.9 | 3.0 | 67.6 | 3.4 | 66.0 | 3.3 | ||||
| MDR1 | 86.8 | 5.8 | 89.2 | 4.6 | 92.4 | 4.4 | 92.4 | 4.6 | ||||
| Escherichia coli | 1,940 | 5,307 | 6,366 | 6,816 | ||||||||
| ESC4 | 76.6 | 13.3 | 79.0 | 13.1 | 81.2 | 14.0 | 81.2 | 15.3 | ||||
| FQ3 | 93.6 | 29.1 | 94.1 | 29.6 | 94.4 | 31.4 | 94.0 | 30.9 | ||||
| Carbapenems | 60.6 | 0.9 | 66.9 | 0.9 | 67.5 | 0.7 | 66.8 | 0.7 | ||||
| MDR1 | 85.4 | 6.1 | 89.5 | 6.0 | 91.7 | 6.7 | 92.7 | 6.5 | ||||
| Enterobacter spp. | 866 | 1,769 | 1,924 | 2,056 | ||||||||
| ESC4 | 92.4 | 27.9 | 91.1 | 26.1 | 92.9 | 28.0 | 94.0 | 27.5 | ||||
| Carbapenems | 61.5 | 2.6 | 65.9 | 2.4 | 68.2 | 4.0 | 67.3 | 3.4 | ||||
| MDR1 | 91.6 | 2.6 | 93.4 | 2.5 | 95.1 | 3.1 | 95.4 | 2.4 | ||||
| Pseudomonas aeruginosa | 1,056 | 2,285 | 2,500 | 2,617 | ||||||||
| AMINOS | 91.9 | 8.4 | 96.3 | 8.0 | 97.3 | 7.6 | 96.3 | 6.6 | ||||
| ESC2 | 92.6 | 11.7 | 93.7 | 10.4 | 94.8 | 10.4 | 94.0 | 9.9 | ||||
| FQ2 | 94.8 | 14.1 | 94.5 | 13.0 | 94.8 | 11.9 | 94.8 | 11.5 | ||||
| Carbapenems | 76.3 | 7.8 | 78.6 | 9.5 | 78.2 | 9.1 | 76.5 | 7.7 | ||||
| PIP/PIPTAZ | 76.5 | 8.0 | 77.0 | 8.2 | 88.4 | 6.9 | 89.8 | 7.4 | ||||
| MDR2 | 95.5 | 5.3 | 96.1 | 5.5 | 96.9 | 4.3 | 96.0 | 4.3 | ||||
| Acinetobacter spp. | 102 | 161 | 177 | 174 | ||||||||
| Carbapenems | 70.6 | 45.8 | 76.4 | 36.6 | 73.4 | 33.1 | 77.6 | 33.3 | ||||
| MDR3 | 95.1 | 40.2 | 95.0 | 39.2 | 94.4 | 33.5 | 97.7 | 32.9 | ||||
NOTE. OX/METH/CEFOX, oxacillin/methicillin/cefoxitin; VAN, vancomycin; ESC4, extended-spectrum cephalosporin (cefepime, cefotaxime, ceftazidime, ceftriaxone); Carbapenems (imipenem, meropenem, doripenem); MDR1, multidrug-resistance (must test either intermediate [I] or resistant [R] to at least 1 drug in 3 of the 5 following classes [ESC4, FQ3, AMINO, carbapenems, & PIP/PIPTAZ]); FQ3, fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin); AMINOS, aminoglycosides (amikacin, gentamicin, tobramycin); ESC2, extended-spectrum cephalosporin (cefepime, ceftazidime); FQ2, fluoroquinolones (ciprofloxacin, levofloxacin); PIP, piperacillin; PIPTAZ, piperacillin/tazobactam; MDR2, multidrug-resistance (must test either I or R to at least 1 drug in 3 of the 5 following classes [ESC2, FQ2, AMINOS, carbapenems, & PIP/PIPTAZ]); MDR3, multidrug-resistance (must test either I or R to at least 1 drug in 3 of the 6 following classes [ESC4, FQ2, AMINOS, carbapenems, PIP/PIPTAZ, & ampicillin/sulbactam]).
If the percent of isolates tested is less than 70%, caution should be used when interpreting the percent resistance.